KURA ONCOLOGY, INC. Employee-related Liabilities, Current
KURA ONCOLOGY, INC. (KURA) had Employee-related Liabilities, Current of $14.34 million as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Accounts Payable and Accrued Liabilities, Current › Accrued Liabilities, Current
us-gaap:EmployeeRelatedLiabilitiesCurrent · last filed 2026-08-12
- 2026-06-30: Employee-related Liabilities, Current $14.34M.
- 2026-03-31: Employee-related Liabilities, Current $10.47M.
- 2025-12-31: Employee-related Liabilities, Current $22.37M.
- 2025-09-30: Employee-related Liabilities, Current $14.60M.
| Period end | Employee-related Liabilities, Current |
|---|---|
| 2026-06-30 | $14.34M 10-Q · filed 2026-08-12 |
| 2026-03-31 | $10.47M 10-Q · filed 2026-05-12 |
| 2025-12-31 | $22.37M 10-Q · filed 2026-08-12 |
| 2025-09-30 | $14.60M 10-Q · filed 2025-11-04 |
| 2025-06-30 | $10.03M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $7.17M 10-Q · filed 2025-05-01 |
| 2024-12-31 | $17.51M 10-K · filed 2026-03-05 |
| 2024-09-30 | $12.48M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $8.93M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $6.06M 10-Q · filed 2024-05-02 |
| 2023-12-31 | $13.15M 10-K · filed 2025-02-28 |
| 2023-09-30 | $9.07M 10-Q · filed 2023-11-02 |
| 2023-06-30 | $6.84M 10-Q · filed 2023-08-09 |
| 2023-03-31 | $5.07M 10-Q · filed 2023-05-10 |
| 2022-12-31 | $10.30M 10-K · filed 2024-02-27 |
| 2022-09-30 | $7.97M 10-Q · filed 2022-11-03 |
| 2022-06-30 | $5.94M 10-Q · filed 2022-08-03 |
| 2022-03-31 | $4.49M 10-Q · filed 2022-05-04 |
| 2021-12-31 | $7.92M 10-K · filed 2023-02-23 |
| 2021-09-30 | $6.44M 10-Q · filed 2021-11-04 |
| 2021-06-30 | $5.30M 10-Q · filed 2021-08-05 |
| 2021-03-31 | $3.86M 10-Q · filed 2021-05-06 |
| 2020-12-31 | $7.02M 10-K · filed 2022-02-24 |
| 2020-09-30 | $5.01M 10-Q · filed 2020-11-05 |
| 2020-06-30 | $3.04M 10-Q · filed 2020-08-06 |
| 2020-03-31 | $2.09M 10-Q · filed 2020-05-04 |
| 2019-12-31 | $3.69M 10-K · filed 2021-02-24 |
| 2019-09-30 | $2.86M 10-Q · filed 2019-11-05 |
| 2019-06-30 | $2.28M 10-Q · filed 2019-08-01 |
| 2019-03-31 | $1.57M 10-Q · filed 2019-05-07 |
| 2018-12-31 | $3.44M 10-K · filed 2020-02-25 |
| 2018-09-30 | $2.08M 10-Q · filed 2018-11-05 |
| 2018-06-30 | $1.56M 10-Q · filed 2018-08-06 |
| 2018-03-31 | $1.05M 10-Q · filed 2018-05-08 |
| 2017-12-31 | $2.35M 10-K · filed 2019-03-05 |
| 2017-09-30 | $1.65M 10-Q · filed 2017-11-07 |
| 2017-06-30 | $1.16M 10-Q · filed 2017-08-07 |
| 2017-03-31 | $802.00K 10-Q · filed 2017-05-15 |
| 2016-12-31 | $1.91M 10-K · filed 2018-03-12 |
| 2016-09-30 | $1.23M 10-Q · filed 2016-11-07 |
| 2016-06-30 | $932.00K 10-Q · filed 2016-08-10 |
| 2016-03-31 | $569.00K 10-Q · filed 2016-05-11 |
| 2015-12-31 | $1.28M 10-K · filed 2017-03-14 |
| 2015-09-30 | $960.00K 10-Q · filed 2015-11-13 |
| 2015-06-30 | $584.00K 10-Q · filed 2015-08-14 |
| 2015-03-31 | $76.00K 10-Q · filed 2015-05-13 |
| 2014-12-31 | $39.00K 10-K · filed 2016-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |